Methods of treating proliferative diseases
Provided herein are methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt or solvate thereof, to human patients, including a specific patient population. Specifically, dosing, dosing schedules or dosing regimens are provided herein. Methods of treating proliferative diseases or FLT-3 mediated diseases in humans are also provided.
1. A spray-dried pharmaceutical composition comprising a compound of Formula I,
or a pharmaceutically acceptable salt or solvate thereof, and hydroxypropyl-β-cyclodextrin.
2. The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable salt is a dihydrochloride salt.
3. The pharmaceutical composition of claim 1 , wherein the solvate is a methanol solvate.
4. The pharmaceutical composition of claim 1 comprising the pharmaceutically acceptable salt of compound of Formula I and hydroxypropyl-β-cyclodextrin in a ratio of about 1:10 based on weight.
5. The pharmaceutical composition of claim 1 , wherein the composition is formulated for single dose administration.
6. The pharmaceutical composition of claim 1 , wherein the composition is formulated for oral administration.